Journal article · 2026
Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial
JAMA · Published 15 November 2026 · DOI 10.1001/jama.2026.24796
In brief
“Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial” is a 2026 journal article by Lin Zhao and 26 co-authors, published in JAMA. OpenAlex counts 0 citations as of 18 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 0
- References
- 21
- Authors
- 27
Abstract
IMPORTANCE: Obesity is a major health problem in China; more pharmacotherapy choices for long-term weight management are needed. OBJECTIVE: To evaluate the efficacy and safety of once-weekly subcutaneous ribupatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, for weight loss in adults in China with overweight or obesity without diabetes. DESIGN, SETTING, AND PARTICIPANTS: This… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zhao, L., Chen, Y., Cheng, Z., Zhu, D., Li, Q., Cai, H., Hui, Y., Wang, Q., Han, J., Cheng, Z., Li, G., Zhong, S., Wang, J., Wang, L., Meng, C., Li, S., Su, H., Xu, Y., ZENG, M., . . . Li, X. (2026). Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.24796
MLA 9
Zhao, Lin, et al. “Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.” JAMA, 2026. https://doi.org/10.1001/jama.2026.24796.
Chicago
Zhao, Lin, Ying Chen, Zhifeng Cheng, Dan Zhu, Qifu Li, Hanqing Cai, Yuan Hui, et al. 2026. “Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.” JAMA. https://doi.org/10.1001/jama.2026.24796.
Harvard
Zhao, L. et al. (2026) ‘Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial’, JAMA. doi:10.1001/jama.2026.24796.
IEEE
L. Zhao et al., “Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial,” JAMA, 2026, doi: 10.1001/jama.2026.24796.
BibTeX
@article{zhao2026once,
title = {{Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial}},
author = {Zhao, Lin and Chen, Ying and Cheng, Zhifeng and Zhu, Dan and Li, Qifu and Cai, Hanqing and Hui, Yuan and Wang, Qi and Han, Junfeng and Cheng, Zongyou and Li, Guiping and Zhong, Shumei and Wang, Jinyang and Wang, Lianwei and Meng, Chao and Li, Shu and Su, Hongye and Xu, Yi and ZENG, MEIFANG and ZUO, Yue and Zhang, Lei and Wei, Wenhua and Wang, L and WANG, YIKE and Lv, Minzhi and Chen, Hong and Li, Xiaoying},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.24796},
url = {https://doi.org/10.1001/jama.2026.24796}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- obesity
- overweight
- weight loss
- GLP-1 receptor agonists
- pharmacotherapy
- dose escalation
- lifestyle intervention
- weight-related comorbidities
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Zhao, L., Chen, Y., Cheng, Z., Zhu, D., Li, Q., Cai, H., Hui, Y., Wang, Q., Han, J., Cheng, Z., Li, G., Zhong, S., Wang, J., Wang, L., Meng, C., Li, S., Su, H., Xu, Y., ZENG, M., . . . Li, X. (2026). Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.24796
How many times has this paper been cited?
0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Lin Zhao, Ying Chen, Zhifeng Cheng, Dan Zhu, Qifu Li, Hanqing Cai, Yuan Hui, Qi Wang, Junfeng Han, Zongyou Cheng, Guiping Li, Shumei Zhong and 15 more.
What is the DOI of this paper?
10.1001/jama.2026.24796, permanently at https://doi.org/10.1001/jama.2026.24796. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.